JATT Acquisition Corp (JATT): history, ownership, mission, how it works & makes money

Born as a Cayman Islands SPAC on March 10, 2021, JATT Acquisition Corp stormed into the market with a $138 million IPO on July 14, 2021 (13,800,000 units at $10.00 each) to pursue a life-sciences business combination, struck a definitive deal with UK clinical-stage biotech Zura Bio in June 2022, secured shareholder approval on March 16, 2023 and closed the transaction on March 20, 2023, after which the combined company began trading on Nasdaq as ZURA / ZURAW on March 21, 2023; the $215 million business combination delivered approximately $65 million in gross cash proceeds to fund R&D into immunology assets targeting IL7, TSLP and IL33 and advancing lead candidates such as ZB‑168 and torudokimab, while the post-merger ownership pool-formerly listed as JATT on the NYSE-now reflects stakes from institutional backers including Magnetar Financial (~8.36% as of Feb 2023), diluted existing holders through new share issuance, and positions the clinical‑stage company to execute CRO/CMO-supported trials, pursue licensing and partnership revenue, and navigate a competitive immunology landscape as of December 16, 2025.

JATT Acquisition Corp (JATT) - Intro

• Incorporation date: March 10, 2021 - Cayman Islands exempted company.
• IPO closed: July 14, 2021 - 13,800,000 units at $10.00 per unit; gross proceeds $138.0 million.
• Target sector: Life sciences and biotechnology (clinical-stage and therapeutics-focused targets).

• Public shareholders of JATT who did not redeem shares prior to the combination converted into holders of the combined company (Zura Bio Limited) common shares.
• SPAC sponsor and sponsor-related parties held founder shares and private placement warrants consistent with typical SPAC structures; dilution and exact sponsor stake varied based on redemptions at SPAC redemption window.
• Post-close cash held by the combined company: approximately $65.0 million (gross) to fund R&D and strategic initiatives.

• Primary mission after combination: advance Zura Bio's clinical-stage immunology and inflammatory disease therapeutics toward clinical milestones and value-creating inflection points.
• Use of proceeds emphasis: support research & development, clinical trials, regulatory filing preparation, and potential inorganic growth through asset or company acquisitions.

• SPAC mechanics (JATT stage): raised capital via IPO into a trust; sought qualifying business combination within defined timeframe; public shareholders had redemption rights prior to closing.
• Business combination mechanics: negotiated a definitive agreement with Zura Bio Limited; obtained shareholder approvals; consummated the merger-JATT renamed Zura Bio and continued as an operating public biotech company.
• Revenue model for the combined biotech (Zura Bio Limited): primarily value creation via R&D progress, milestone payments, licensing, partnerships, and potential future commercial revenues if pipeline assets reach approval and commercialization.

JATT Acquisition Corp (JATT): History

• Pre-combination status: Public SPAC on NYSE (ticker: JATT)
• Business combination closed: Combined company listed on Nasdaq (ZURA, ZURAW) - trading began March 21, 2023
• Significant pre-combination institutional holder: Magnetar Financial - ~8.36% ownership as of February 2023
• Result of combination: New shares issued, dilution of legacy JATT shareholders, redistribution of ownership to include Zura Bio shareholders
• Ownership snapshot (post-close): Percentages determined by business combination agreement and subsequent trades - integrated cap table as of Dec 16, 2025 reflects combined ownership

• Types of holders in the combined cap table:
  • Legacy JATT public shareholders (pre-SPAC investors)
  • Zura Bio legacy shareholders (equity exchange recipients)
  • Institutional investors (e.g., Magnetar Financial)
  • New public investors trading ZURA / ZURAW post-combination

JATT Acquisition Corp (JATT): Ownership Structure

• Mission: advance a multi-asset immunology pipeline (IL7, TSLP, IL33) to deliver best-in-class therapies.
• Values: innovation, scientific excellence, patient-centric development, transparent governance, regulatory compliance.
• Strategic focus: partnerships and collaborations to accelerate R&D and commercial readiness.
• Leadership pedigree: senior team with decades of biotech/pharma experience and prior Arena Pharmaceuticals alumni.

• How it works: JATT sources or partners with biotech assets/teams to accelerate clinical development and commercialization; structure typically combines sponsor equity, public SPAC proceeds, and PIPE financing to fund development milestones.
• How it makes money: value creation via de-risking clinical programs, milestone-driven partnerships, licensing, and eventual commercial revenues if candidates reach market - SPAC shareholders capture upside through post-merger equity appreciation.

JATT Acquisition Corp (JATT): Mission and Values

• Capital formation: JATT raises capital from public investors through an initial public offering (IPO), selling units typically comprised of common shares and warrants at $10.00 per unit (industry standard).
• Trust and redemption: IPO proceeds (less offering expenses) are placed in a trust account invested in short-term instruments; public investors may redeem shares for their pro rata portion of the trust upon a proposed business combination.
• Sponsor economics: Sponsors typically receive a promote (commonly 20% of post-IPO equity) to compensate for sourcing and executing transactions, creating alignment with public shareholders' upside.
• Transaction window: JATT generally has a specified period (commonly 18-24 months) to complete a business combination; if no transaction is completed within the timeline, the SPAC liquidates and returns trust funds to public holders.

• Board and management: A board of directors and executive leadership team with dealmaking, industry, legal and financial experience govern strategic direction and approve acquisitions.
• Advisors and partners: JATT engages financial advisors, legal counsel, and accounting firms to support transaction execution and regulatory compliance.
• Independent committees: Independent board members typically review conflicts and vote on business combination approvals to protect public investors' interests.

• Post-transaction equity appreciation: Sponsors and public holders benefit if the target company's public-market valuation rises following the business combination.
• Warrants and sponsor promote: Value may be created through warrants issued at IPO and the sponsor's promote, which converts into common equity after the transaction.
• Transaction and advisory fees: Sponsors and affiliated parties may receive fees for structuring, advisory, or backstop services, disclosed in transaction proxies and agreements.
• De-SPAC PIPE investments: Private investment in public equity (PIPE) commitments often accompany deals, providing additional financing and potential fee or advisory revenue streams.

• Target sourcing: Proprietary deal flow through industry networks, sector-focused scouting, and intermediary relationships to identify scalable targets.
• Due diligence: Comprehensive commercial, financial, legal, tax, and technical diligence-often coordinated with external counsel and auditors-to validate target prospects and mitigate risk.
• Capital structuring: Negotiation of purchase consideration, equity retention structures, earn-outs, and PIPEs to align incentives and secure adequate post-merger capital.
• Post-merger integration planning: Early integration planning to drive revenue synergies, cost optimization, and governance transitions after closing.

• Sponsors and insiders: Provide initial capital, bear organizational expenses, and hold the promote; their equity stake aligns incentives with public investors to achieve value-accretive combinations.
• Public shareholders: Provide the majority of IPO capital via unit purchases, with redemption rights protecting capital if a deal is unsatisfactory.
• PIPE investors and strategic partners: Offer supplemental capital, sector expertise, and credibility to the combination, often taking significant minority stakes in the post-merger company.

• External advisors: Investment banks, accounting firms, and legal advisors provide transaction execution and regulatory support.
• Industry specialists: Technical and market experts assist in validating target business models, product pipelines, or go-to-market strategies.
• Contract service providers: For combined companies (e.g., in life sciences or manufacturing), JATT-supported deals often rely on CROs, CMOs, or outsourced vendors to scale operations efficiently.

• Proxy statements: Detailed disclosure of target financials, sponsor conflicts, fees, and post-transaction capital structure prior to shareholder votes.
• Audit and accounting: Target carve-out or historical financials audited per SEC standards for public reporting.
• Board composition post-merger: Negotiated director slate and governance terms to ensure experienced oversight following closing.

JATT Acquisition Corp (JATT): How It Works

• Zura Bio Limited generates revenue through the development and commercialization of its therapeutic candidates, including licensing agreements, partnerships, and potential product sales.
• The company has secured funding through business combinations, such as the $215 million business combination with JATT Acquisition Corp, which provided approximately $65 million in gross cash proceeds to support its operations.
• Zura Bio Limited may enter into strategic partnerships and collaborations with other biotechnology or pharmaceutical companies to co-develop and co-commercialize its products, sharing in the resulting revenues.
• The company may also receive milestone payments and royalties from licensing agreements related to its intellectual property.
• Zura Bio Limited's revenue model is focused on monetizing its pipeline of immunology assets through various channels, including partnerships, licensing, and eventual product commercialization.
• As of December 16, 2025, the company's revenue streams are primarily derived from its ongoing research and development activities and any strategic partnerships or licensing agreements it has established.

• Upfront financing from the SPAC business combination (net ~ $65M gross cash proceeds) to fund clinical trials, preclinical work, and corporate operations.
• License and collaboration revenues: upfronts, development milestones, regulatory milestones, and royalties on future product sales.
• Equity and debt financings post-merger to extend runway and support late-stage development and commercialization activities.
• Potential milestone-driven non-dilutive payments from partners for achieving clinical or regulatory endpoints.

• Clinical progress - advancing assets through IND/clinical milestones triggers partner payments and increases valuation.
• Strategic licensing - out-licensing or co-development deals for specific regions or indications to capture upfront and milestone revenue.
• Royalties - long-term recurring revenue once products achieve commercial sales under licensing agreements.
• Follow-on financings - equity/debt raises to fund commercialization or late-stage trials, diluting or leveraging equity as needed.

JATT Acquisition Corp (JATT): How It Makes Money

• Primary revenue/value drivers: sponsor promote on deals, equity appreciation in merger targets, warrant exercises, and advisory/arrangement fees tied to transactions.
• Capital base: proceeds held in trust earn modest interest until a business combination; leftover cash post-merger funds initial operating needs of the combined company.
• Risk vectors: target selection, dilution from PIPEs and warrants, regulatory/go-to-market execution of merged entities.

• Sector focus: JATT targets high-opportunity sectors (including biotechnology) where successful mergers can unlock outsized equity returns.
• Competitive landscape: competes with other SPACs and strategic acquirers; success depends on sourcing differentiated targets and structuring compelling deals.
• Management edge: deal-sourcing networks, sector expertise, and track record influence ability to attract PIPE investors and strategic partners.
• Future contingency (as of Dec 16, 2025): outlook hinges on successful completion of business combinations, post-merger execution, regulatory approvals where relevant, and the ability to retain investor confidence.

• Pre-merger: interest income on trust assets; potential fee income from advisory relationships.
• Transaction: sponsor promote (equity stake post-combination), structuring/arrangement fees, and capital raises (PIPEs) that can create uplift.
• Post-merger: equity appreciation if the merged company grows, dilution management through financing strategy, and potential monetization events (secondary sales, IPOs, acquisitions).

• Clinical-stage catalysts drive valuation inflection points (trial readouts, INDs, regulatory filings).
• Partnerships/licensing with larger pharma accelerate commercialization and de-risk timelines.
• Differentiation versus peers is critical: unique mechanism, clear IP, and superior clinical data increase probability of value creation.